NYSE:IQV - Iqvia Stock Price, Price Target & More

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) released its earnings results on Wednesday, May, 2nd. The medical research company reported $1.34 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.27 by $0.07. The medical research company earned $2.56 billion during the quarter, compared to analysts' expectations of $2.42 billion. Iqvia had a net margin of 13.07% and a return on equity of 13.35%. Iqvia's revenue was up 34.1% compared to the same quarter last year. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share (EPS) guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.Iqvia also updated its Q2 guidance to $1.17-1.24 EPS.

18 equities research analysts have issued 1-year target prices for Iqvia's shares. Their predictions range from $93.42 to $128.00. On average, they expect Iqvia's share price to reach $110.9659 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View Analyst Ratings for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and VIRALYTICS Ltd/S (VRACY).

News stories about IQV stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Iqvia earned a media sentiment score of 0.09 on Accern's scale. They also gave news headlines about the medical research company an impact score of 46.28 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Iqvia's stock is owned by a number of of institutional and retail investors. Top institutional investors include Hardman Johnston Global Advisors LLC (0.21%), Retirement Systems of Alabama (0.16%), Arvest Bank Trust Division (0.11%), Howard Capital Management (0.06%), Bank of Montreal Can (0.06%) and Fisher Asset Management LLC (0.05%). Company insiders that own Iqvia stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Hardman Johnston Global Advisors LLC, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Hartford Investment Management Co., Bremer Trust National Association, Fisher Asset Management LLC, Nisa Investment Advisors LLC and Westpac Banking Corp. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for Iqvia.

IQV stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Fjarde AP Fonden Fourth Swedish National Pension Fund, Clinton Group Inc., Cornerstone Wealth Management LLC, NN Investment Partners Holdings N.V., Ironsides Asset Advisors LLC, Gulf International Bank UK Ltd and Vision Capital Management Inc.. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $111.11.

Iqvia has a market capitalization of $22.63 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.

Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]